Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Irpagratinib - Abbisko Therapeutics

Next Previous
Drug Profile

Irpagratinib - Abbisko Therapeutics

Alternative Names: ABSK 011

Latest Information Update: 12 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbisko Therapeutics
  • Class 1 ring heterocyclic compounds; Acrylamides; Amines; Antineoplastics; Azetidines; Ethers; Fluorobenzenes; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action Type 4 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Liver cancer

Most Recent Events

  • 08 Jun 2025 Asan Medical Center in collaboration with Abbisko Therapeutics plans a phase II trial in Hepatocellular carcinoma (Late-stage disease, Inoperable/unresectable, Second-line therapy or greater) in November 2025 (PO) (NCT07010497)
  • 26 May 2025 Irpagratinib receives Breakthrough Therapy status for Liver cancer in China
  • 30 Apr 2025 Phase-II clinical trials in Liver cancer (Combination therapy, Inoperable/Unresectable, Second-line therapy or greater, Metastatic disease) in China (PO) (NCT06978933)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top